The more generalized IRS and CIRS activation, as well as the Th1 profile and Th17-axis, are therapeutic targets to prevent subsequent relapses in a subset of remitted RRMS patients. This evidence concerns the gene IARS1 and relapsing-remitting multiple sclerosis.